Dr. Yungan Tao is radiation oncologist specializing in head and neck, dermatology, and endocrinology at the Department of Radiation Oncology, Gustave Roussy Cancer Campus.

He currently serves as President-Elect and is a member of both the Board of Directors and the Scientific Committee of the French Head and Neck Oncology Radiotherapy Group (GORTEC). 

Dr. Tao also represents the French intergroupe/GORTEC as a board member in the Head and Neck Cancer International Group (HNCIG).   

He is an Expert Panelist for nasopharyngeal cancer project at the International Atomic Energy Agency (IAEA). Additionally, he is the Head and Neck Cancer Track Co-Chair (representing Europe) on the Scientific Committee of ESMO (European Society for Medical Oncology) Asia Congress 2025 and serves as the ESMO Chair for the International Congress on Innovative Approaches in Head and Neck Oncology (ICHNO).

Dr. Tao is the principle investigator or co-principal investigator for several phase II/III clininical trials, including GORTEC 2007-01, PembroRad, DEBIO-1143-201, REACH, and Nivo-Postop. His research focuses on the use of new radiotherapy technologies and the combination of targeted therapies or immunotherapies with (chemo) radiotherapy. He is also involved in several large-scale phase III trials such as KeyNote-412, KeyNote-689, and Trilynx.